Lexicon's Sotagliflozin in HCM: A High-Risk Phase 3 Bet on a Novel Mechanism Without Precedent or Proof-of-Concept

Lexicon Completes Enrollment for Pivotal SONATA-HCM Study

Lexicon Pharmaceuticals has announced the completion of patient enrollment for its pivotal Phase 3 SONATA-HCM study, evaluating sotagliflozin in symptomatic non-obstructive (nHCM) and obstructive (oHCM) hypertrophic cardiomyopathy. The study significantly surpassed its target of 500 patients, enrolling participants across over 130 sites in 20 countries. Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, is being assessed for its potential as a differentiated treatment option for HCM patients, particularly those with nHCM where options are limited. Topline results from this large-scale, randomized, double-blind, placebo-controlled trial are expected in the first quarter of 2027.

• The SONATA-HCM study is notable as the only ongoing Phase 3 trial and the largest to date encompassing both non-obstructive and obstructive hypertrophic cardiomyopathy. It substantially exceeded its enrollment target of 500 patients, recruiting from over 130 sites across 20 countries. The final study population includes a significant majority of patients with non-obstructive HCM, addressing a critical unmet need for effective treatments in this specific patient group, while also providing a meaningful cohort for obstructive HCM evaluation.
• Sotagliflozin, discovered through Lexicon’s gene science approach, is an oral dual inhibitor of SGLT1 and SGLT2 proteins, which are crucial for glucose and sodium regulation in the gastrointestinal tract and kidney, respectively. This unique mechanism of action differentiates it from currently available treatments for HCM. Lexicon believes sotagliflozin has the potential to be a novel and well-tolerated therapeutic option that can complement existing guideline-directed therapies, including cardiac myosin inhibitors, for symptomatic HCM patients.
• The primary efficacy endpoint for the SONATA-HCM trial is the improvement in symptoms, measured by the change from baseline to week 26 in the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ CSS). This endpoint aims to assess the drug's impact on daily function and patient-reported outcomes. Experts emphasize the significant unmet need for additional treatment options that can effectively address persistent symptoms and improve the quality of life for individuals living with hypertrophic cardiomyopathy.

Addressing the Unmet Needs in Symptomatic HCM Treatment

Current therapeutic strategies for hypertrophic cardiomyopathy (HCM) provide symptomatic relief but are hindered by several key limitations. These challenges range from the lack of disease-modifying effects in established treatments to specific difficulties in managing patient subpopulations and comorbidities. A comprehensive view of these limitations highlights significant unmet needs and directs future research toward more effective, personalized management of both obstructive and non-obstructive HCM.

• Palliative Nature of Conventional Therapies: Traditional medical treatments, such as β-blockers and calcium channel blockers, primarily alleviate symptoms associated with left ventricular outflow tract (LVOT) obstruction. They do not, however, address the underlying pathophysiology of sarcomeric hypercontractility, and patients with refractory symptoms may require invasive septal reduction therapies.

• Lack of Influence on Disease Progression: Even established invasive procedures like surgical myectomy, transcoronary ablation of septal hypertrophy (TASH), and dual-chamber pacing have not been proven to alter the natural history of HCM. Despite effectively reducing gradients and improving clinical symptoms, their long-term impact on disease progression remains unconfirmed, and robust comparative data between these modalities are scarce.

• Challenges in Managing Comorbid Hypertension: The coexistence of hypertension, which affects an estimated 40-60% of adults with HCM, presents a significant clinical dilemma. Standard vasodilatory antihypertensives can exacerbate LVOT obstruction, confounding treatment. While this comorbidity is linked to a higher prevalence of atrial fibrillation and stroke in HCM patients, its effect on ventricular arrhythmias and mortality is less clear, representing a major evidence gap.

• Limited Efficacy in Non-Obstructive HCM (nHCM): Novel cardiac myosin inhibitors have shown inconsistent results in the nHCM population. For instance, in the ODYSSEY-HCM trial, mavacamten did not meet its primary endpoints for improving exercise capacity or patient-reported health status, despite demonstrating favorable biological activity on cardiac biomarkers and remodeling parameters.

• Impact of Socioeconomic Disparities: Patient outcomes are not solely dependent on clinical factors. Research indicates that socioeconomic status, measured by neighborhood median household income, is an independent predictor of long-term outcomes in HCM. This suggests that non-clinical factors create disparities and present an additional, often overlooked, challenge in patient management.

Unpacking the SONATA-HCM Trial Design and Endpoints

Recent pivotal trials have reshaped the therapeutic landscape for hypertrophic cardiomyopathy (HCM), evaluating novel mechanisms like cardiac myosin inhibition. These studies have employed rigorous designs and specific endpoints to demonstrate efficacy in both obstructive (oHCM) and non-obstructive (nHCM) forms of the disease. The table below summarizes the key design parameters and endpoints from these landmark clinical trials.

Sotagliflozin's Dual Approach: A New Hope for Hypertrophic Cardiomyopathy?

The completion of enrollment for the SONATA-HCM study represents a pivotal moment for Lexicon Pharmaceuticals and the broader hypertrophic cardiomyopathy (HCM) community. HCM is a challenging genetic heart condition, and the lack of effective pharmacological treatments, especially for the non-obstructive form, highlights a significant unmet medical need. Sotagliflozin, with its unique dual inhibition of SGLT1 and SGLT2, is poised to potentially offer a differentiated therapeutic approach.

Existing evidence for sotagliflozin in other cardiometabolic conditions provides a strong foundation. In patients with type 2 diabetes and recent worsening heart failure, it significantly reduced cardiovascular deaths and hospitalizations, and notably increased 'days alive and out of hospital.' Furthermore, in patients with type 2 diabetes, chronic kidney disease, and cardiovascular risk factors, sotagliflozin demonstrated a reduction in major adverse cardiovascular events, including myocardial infarction and stroke – an ischemic benefit not consistently observed with SGLT2-only inhibitors. This suggests that its dual mechanism may confer broader cardiovascular protection, which could be highly relevant for HCM patients.

However, the path forward is not without considerations. A key concern is the documented risk of diabetic ketoacidosis (DKA) observed in earlier trials for type 1 diabetes, which previously impacted its regulatory journey in the US. While HCM is distinct from diabetes, careful patient selection and monitoring protocols will be crucial to mitigate this risk. Additionally, the heart failure treatment landscape is increasingly competitive, with several SGLT2 inhibitors already well-established. Sotagliflozin will need to demonstrate clear, compelling benefits in HCM to differentiate itself and secure a strong position. The history of early termination for some of its previous pivotal trials due to funding issues also underscores the importance of robust data and clear interpretation for the upcoming SONATA-HCM results. If successful, sotagliflozin could not only provide a much-needed treatment for HCM but also further validate the therapeutic potential of dual SGLT1/SGLT2 inhibition across a spectrum of cardiovascular diseases.